Advances in genetic testing and optimization of clinical management in children and adults with epilepsy

References

• Striano P. Epilepsy towards the next decade: new trends and hopes in epileptology. Basel: Springer International Publishing; 2015.
   Google Scholar
• Andrade DM, Minassian BA. Genetics of epilepsies. Expert Rev Neurother. 2007;7:727–734.
   PubMedGoogle Scholar
• Orsini A, Zara F, Striano P. Recent advances in epilepsy genetics. Neurosci Lett. 2018;667:4–9.
   PubMed Web of Science ®Google Scholar
• Symonds JD, Zuberi SM, Johnson MR. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment. Curr Opin Neurol. 2017;30:193–199.
   PubMed Web of Science ®Google Scholar
• Mantegazza M, Rusconi R, Scalmani P, et al. Epileptogenic ion channel mutations: from bedside to bench and, hopefully, back again. Epilepsy Res. 2010;92:1–29.
   PubMed Web of Science ®Google Scholar
• Nicita F, De Liso P, Danti FR, et al. The genetics of monogenic idiopathic epilepsies and epileptic encephalopathies. Seizure. 2012;21:3–11.
   PubMed Web of Science ®Google Scholar
• Perry MS, Poduri A. Two studies, one message: high yield of genetic testing in infants and young children with severe epilepsies. Epilepsy Curr. 2018;18:24–26.
   PubMed Web of Science ®Google Scholar
• Bianchi A. Definition of the phenotype for genetic studies. Chapter 5. In perinatal brain damage: from pathogenesis to neuroprotection. London-Paris: John Libbey Eurotext; 2009.
   Google Scholar
• Olson HE, Poduri A, Pearl PL. Genetic forms of epilepsies and other paroxysmal disorders. Semin Neurol. 2014;34:266–279.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:522–530.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Cross JH, D’Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531–542.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Definition of refractory epilepsy: defining the indefinable? Lancet Neurol. 2010;9:27–29.
   PubMed Web of Science ®Google Scholar
• Peljto AL, Barker-Cummings C, Vasoli VM, et al. Familial risk of epilepsy: a population-based study. Brain. 2014;137:795–805.
   PubMed Web of Science ®Google Scholar
• Christensen J, Overgaard M, Parner ET, et al. Risk of epilepsy and autism in full and half siblings-A population-based cohort study. Epilepsia. 2016;57:2011–2018.
   PubMed Web of Science ®Google Scholar
• Bennett RL, French KS, Resta RG, et al. Standardized human pedigree nomenclature: update and assessment of the recommendations of the national society of genetic counselors. J Genet Couns. 2008;17:424–433.
   PubMedGoogle Scholar
• Seneviratne U, Cook MJ, D’Souza WJ. Electroencephalography in the diagnosis of genetic generalized epilepsy syndromes. Front Neurol. 2017;8:499.
   PubMed Web of Science ®Google Scholar
• Giannakodimos S, Panayiotopoulos CP. Eyelid myoclonia with absences in adults: a clinical and video-EEG study. Epilepsia. 1996;37:36–44.
   PubMed Web of Science ®Google Scholar
• Hrachovy RA, Frost JD Jr. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/west syndrome). J Clin Neurophysiol. 2003;20:408–425.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Pellacani S. Benign childhood focal epilepsies. Epilepsia. 2012;53:9–18.
   PubMed Web of Science ®Google Scholar
• Kim SH, Korff CM, Kim AJ, et al. A practical, simple, and useful method of categorizing interictal EEG features in children. Neurology. 2015;85:471–478.
   PubMed Web of Science ®Google Scholar
• Assi L, Saklawi Y, Karam PE, et al. Treatable genetic metabolic epilepsies. Curr Treat Options Neurol. 2017;19:30.
   PubMed Web of Science ®Google Scholar
• Papetti L, Parisi P, Leuzzi V, et al. Metabolic epilepsy: an update. Brain Dev. 2013;35:827–841.
   PubMed Web of Science ®Google Scholar
• Wolf B. The neurology of biotinidase deficiency. Mol Genet Metab. 2011;104:27–34.
   PubMed Web of Science ®Google Scholar
• Kirkham FJ. Indications for the performance of neuroimaging in children. Handbook of Clinical Neurology. 2016;136:1275–1290.
   PubMedGoogle Scholar
• Bernasconi A, Cendes F, Theodore WH, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the international league against epilepsy neuroimaging. Epilepsia. 2019;60:1054–1068.
   PubMed Web of Science ®Google Scholar
• Lange M, Kasper B, Bohring A, et al. 47 patients with FLNA associated periventricular nodular heterotopia. Orphanet J Rare Dis. 2015;10:134.
   PubMed Web of Science ®Google Scholar
• El Achkar CM, Olson HE, Poduri A, et al. The genetics of the epilepsies. Curr Neurol Neurosci Rep. 2015;15:39.
   PubMed Web of Science ®Google Scholar
• Epilepsy Phenome/Genome Project & Epi4K Consortium. Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. Ann Neurol. 2015;78:323–328.
   Google Scholar
• de Kovel CG, Trucks H, Helbig I, et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain. 2010;133:23–32.
   PubMed Web of Science ®Google Scholar
• Mefford HC, Muhle H, Ostertag P, et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet. 2010;6:e1000962.
   PubMed Web of Science ®Google Scholar
• Mullen SA, Carvill GL, Bellows S, et al. Copy number variants are frequent in genetic generalized epilepsy with intellectual disability. Neurology. 2013;81:1507–1514.
   PubMed Web of Science ®Google Scholar
• Striano P, Coppola A, Paravidino R, et al. Clinical significance of rare copy number variations in epilepsy: a case-control survey using microarray-based comparative genomic hybridization. Arch Neurol. 2012;69:322–330.
   PubMedGoogle Scholar
• Olson H, Shen Y, Avallone J, et al. Copy number variation plays an important role in clinical epilepsy. Ann Neurol. 2014;75:943–958.
   PubMed Web of Science ®Google Scholar
• Møller RS, Dahl HA, Helbig I. The contribution of next generation sequencing to epilepsy genetics. Expert Rev Mol Diagn. 2015;15:1531–1538.
   PubMed Web of Science ®Google Scholar
• Myers CT, Mefford HC. Advancing epilepsy genetics in the genomic era. Genome Med. 2015;7:91.
   PubMed Web of Science ®Google Scholar
• Mefford HC. Clinical genetic testing in epilepsy. Epilepsy Curr. 2015;15:197–201.
   PubMed Web of Science ®Google Scholar
• Weber YG, Biskup S, Helbig KL, et al. The role of genetic testing in epilepsy diagnosis and management. Expert Rev Mol Diagn. 2017;17:739–750.
   PubMed Web of Science ®Google Scholar
• Costain G, Cordeiro D, Matviychuk D, et al. Clinical application of targeted next-generation sequencing panels and whole exome sequencing in childhood epilepsy. Neuroscience. 2019;418:291–310.
   PubMed Web of Science ®Google Scholar
• Jang SS, Kim SY, Kim H, et al. Diagnostic yield of epilepsy panel testing in patients with seizure onset within the first year of life. Front Neurol. 2019;10:988.
   PubMed Web of Science ®Google Scholar
• Staněk D, Laššuthová P, Štěrbová K, et al. Detection rate of causal variants in severe childhood epilepsy is highest in patients with seizure onset within the first four weeks of life. Orphanet J Rare Dis. 2018;13:71.
   PubMed Web of Science ®Google Scholar
• Ko A, Youn SE, Kim SH, et al. Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy. Epilepsy Res. 2018;141:48–55.
   PubMed Web of Science ®Google Scholar
• Dunn P, Albury CL, Maksemous N, et al. Next generation sequencing methods for diagnosis of epilepsy syndromes. Front Genet. 2018;9:20.
   PubMed Web of Science ®Google Scholar
• Trump N, McTague A, Brittain H, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet. 2016;53:310–317.
   PubMed Web of Science ®Google Scholar
• Bowdin S, Gilbert A, Bedoukian E, et al. Recommendations for the integration of genomics into clinical practice. Genet Med. 2016;18:1075–1084.
   PubMed Web of Science ®Google Scholar
• Tetreault M, Bareke E, Nadaf J, et al. Whole-exome sequencing as a diagnostic tool: current challenges and future opportunities. Expert Rev Mol Diagn. 2015;15:749–760.
   PubMed Web of Science ®Google Scholar
• Lindy AS, Stosser MB, Butler E, et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia. 2018;59:1062–1071.
   PubMed Web of Science ®Google Scholar
• Bennett CA, Petrovski S, Oliver KL, et al. ExACtly zero or once: A clinically helpful guide to assessing genetic variants in mild epilepsies. Neurol Genet. 2017;3:e163. eCollection 2017 Aug.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405–424.
   PubMed Web of Science ®Google Scholar
• Dunn P, Albury CL, Maksemous N, et al. Next generation sequencing methods for diagnosis of epilepsy syndromes. Front Genet. 2018;9:20.
   PubMed Web of Science ®Google Scholar
• Cheung SW, Bi W. Novel applications of array comparative genomic hybridization in molecular diagnostics. Expert Rev Mol Diagn. 2018;18:531–542.
   PubMed Web of Science ®Google Scholar
• Monlong J, Girard SL, Meloche C, et al. Global characterization of copy number variants in epilepsy patients from whole genome sequencing. PLoS Genet. 2018;14:e1007285.
   PubMed Web of Science ®Google Scholar
• Pirooznia M, Goes FS, Zandi PP. Whole-genome CNV analysis: advances in computational approaches. Front Genet. 2015;6:138.
   PubMed Web of Science ®Google Scholar
• Nolan D, Carlson M. Whole exome sequencing in pediatric neurology patients: clinical implications and estimated cost analysis. J Child Neurol. 2016;31:887–894.
   PubMed Web of Science ®Google Scholar
• Schwarze K, Buchanan J, Taylor JC, et al. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20:1122–1130.
   PubMed Web of Science ®Google Scholar
• Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005-2009. Epilepsia. 2010;51:676–685.
   PubMed Web of Science ®Google Scholar
• Arsov T, Mullen SA, Damiano JA, et al. Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency. Epilepsia. 2012;53:e204–7.
   PubMed Web of Science ®Google Scholar
• Larsen J, Johannesen KM, Ek J, et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia. 2015;56:e203–8.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Delgado-Escueta AV, Aguan K, et al. Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet. 2004;36:842–849.
   PubMed Web of Science ®Google Scholar
• Zara F, Specchio N, Striano P, et al. Genetic testing in benign familial epilepsies of the first year of life: clinical and diagnostic significance. Epilepsia. 2013;54:425–436.
   PubMed Web of Science ®Google Scholar
• Gardella E, Becker F, Møller RS, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol. 2016;79:428–436.
   PubMed Web of Science ®Google Scholar
• Grinton BE, Heron SE, Pelekanos JT, et al. Familial neonatal seizures in 36 families: clinical and genetic features correlate with outcome. Epilepsia. 2015;56:1071–1080.
   PubMed Web of Science ®Google Scholar
• Pisano T, Numis AL, Heavin SB, et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia. 2015;56:685–691.
   PubMed Web of Science ®Google Scholar
• van Vliet R, Breedveld G, de Rijk-van Andel J, et al. PRRT2 phenotypes and penetrance of paroxysmal kinesigenic dyskinesia and infantile convulsions. Neurology. 2012;79:777–784.
   PubMed Web of Science ®Google Scholar
• Trivisano M, Terracciano A, Milano T, et al. Mutation of CHRNA2 in a family with benign familial infantile. Epilepsia. 2015;56:e53–7.
   PubMed Web of Science ®Google Scholar
• Symonds JD, Zuberi SM, Stewart K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019;142:2303–2318.
   PubMed Web of Science ®Google Scholar
• Chen WJ, Lin Y, Xiong ZQ, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet. 2011;43:1252–1255.
   PubMed Web of Science ®Google Scholar
• Heron SE, Grinton BE, Kivity S, et al. PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet. 2012;90:152–160.
   PubMed Web of Science ®Google Scholar
• Méneret A, Grabli D, Depienne C, et al. PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population. Neurology. 2012;79:170–174.
   PubMed Web of Science ®Google Scholar
• Lemke JR, Lal D, Reinthaler EM, et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet. 2013;45:1067–1072.
   PubMed Web of Science ®Google Scholar
• Licchetta L, Pippucci T, Baldassari S, et al. Sleep-related hypermotor epilepsy (SHE): contribution of known genes in 103 patients. Seizure. 2019;74:60–64.
   PubMedGoogle Scholar
• Menghi V, Bisulli F, Tinuper P, et al. Sleep-related hypermotor epilepsy: prevalence, impact and management strategies. Nat Sci Sleep. 2018;10:317–326.
   PubMed Web of Science ®Google Scholar
• Tinuper P, Bisulli F, Cross JH, et al. Definition and diagnostic criteria of sleep-related hypermotor epilepsy. Neurology. 2016;86:1834–1842.
   PubMed Web of Science ®Google Scholar
• Aridon P, Marini C, Di Resta C, et al. Increased sensitivity of the neuronal nicotinic receptor alpha 2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. Am J Hum Genet. 2006;79:342–350.
   PubMed Web of Science ®Google Scholar
• Heron SE, Smith KR, Bahlo M, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 2012;44:1188–1190.
   PubMed Web of Science ®Google Scholar
• Korenke GC, Eggert M, Thiele H, et al. Nocturnal frontal lobe epilepsy caused by a mutation in the GATOR1 complex gene NPRL3. Epilepsia. 2016;57:e60–3.
   PubMed Web of Science ®Google Scholar
• Michelucci R, Pasini E, Malacrida S, et al. Low penetrance of autosomal dominant lateral temporal epilepsy in Italian families without LGI1 mutations. Epilepsia. 2013;54:1288–1297.
   PubMed Web of Science ®Google Scholar
• Rosanoff MJ, Ottman R. Penetrance of LGI1 mutations in autosomal dominant partial epilepsy with auditory features. Neurology. 2008;71:567–571.
   PubMed Web of Science ®Google Scholar
• Ottman R, Winawer MR, Kalachikov S, et al. LGI1 mutations in autosomal dominant partial epilepsy with auditory features. Neurology. 2004;62:1120–1126.
   PubMed Web of Science ®Google Scholar
• Bisulli F, Tinuper P, Scudellaro E, et al. A de novo LGI1 mutation in sporadic partial epilepsy with auditory features. Ann Neurol. 2004;56:455–456.
   PubMed Web of Science ®Google Scholar
• Dazzo E, Fanciulli M, Serioli E, et al. Heterozygous reelin mutations cause autosomal-dominant lateral temporal epilepsy. Am J Hum Genet. 2015;96:992–1000.
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Scheffer IE. Febrile seizures: genetics and relationship to other epilepsy syndromes. Curr Opin Neurol. 1998;11:129–134.
   PubMed Web of Science ®Google Scholar
• Kivity S, Oliver KL, Afawi Z, et al. SCN1A clinical spectrum includes the self-limited focal epilepsies of childhood. Epilepsy Res. 2017;131:9–14.
   PubMed Web of Science ®Google Scholar
• Bonanni P, Malcarne M, Moro F, et al. Generalized epilepsy with febrile seizures plus (GEFS+): clinical spectrum in seven Italian families unrelated to SCN1A, SCN1B, and GABRG2 gene mutations. Epilepsia. 2004;45:149–158.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Burgess R, Malone JP, et al. Genetic epilepsy with febrile seizures plus: refining the spectrum. Neurology. 2017;89:1210–1219.
   PubMed Web of Science ®Google Scholar
• Kalser J, Cross JH. The epileptic encephalopathy jungle - from Dr West to the concepts of aetiology-related and developmental encephalopathies. Curr Opin Neurol. 2018;31:216–222.
   PubMed Web of Science ®Google Scholar
• McTague A, Howell KB, Cross JH, et al. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. 2016;15:304–316.
   PubMed Web of Science ®Google Scholar
• Jehi L, Wyllie E, Devinsky O. Epileptic encephalopathies: optimizing seizure control and developmental outcome. Epilepsia. 2015;56:1486–1489.
   PubMed Web of Science ®Google Scholar
• Carvill GL, McMahon JM, Schneider A, et al. Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures. Am J Hum Genet. 2015;96:808–815.
   PubMed Web of Science ®Google Scholar
• Nieh SE, Sherr EH. Epileptic encephalopathies: new genes and new pathways. Neurotherapeutics. 2014;11:796–806.
   PubMed Web of Science ®Google Scholar
• Kuzniecky R. Epilepsy and malformations of cortical development: new developments. Curr Opin Neurol. 2015;28:151–157.
   PubMed Web of Science ®Google Scholar
• Jamuar SS, Lam AT, Kircher M, et al. Somatic mutations in cerebral cortical malformations. N Engl J Med. 2014;371:733–743.
   PubMed Web of Science ®Google Scholar
• Barkovich AJ, Guerrini R, Kuzniecky RI, et al. A developmental and genetic classification for malformations of cortical development: update. Brain. 2012;135:1348–1369.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Dobyns WB. Malformations of cortical development: clinical features and genetic causes. Lancet Neurol. 2014;13:710–726.
   PubMed Web of Science ®Google Scholar
• Pavone P, Praticò AD, Rizzo R, et al. A clinical review on megalencephaly: A large brain as a possible sign of cerebral impairment. Medicine (Baltimore). 2017;96:e6814.
   PubMed Web of Science ®Google Scholar
• Rivière JB, Mirzaa GM, O’Roak BJ, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012;44:934–940.
   PubMed Web of Science ®Google Scholar
• Mirzaa GM, Conway RL, Gripp KW, et al. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactylypolymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am J Med Genet A. 2012;158A:269–291.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Filippi T. Neuronal migration disorders, genetics, and epileptogenesis. J Child Neurol. 2005;20:287–299.
   PubMed Web of Science ®Google Scholar
• Fry AE, Cushion TD, Pilz DT. The genetics of lissencephaly. Am J Med Genet C Semin Med Genet. 2014;166C:198–210.
   PubMedGoogle Scholar
• Kim JK, Lee JH. Mechanistic target of rapamycin pathway in epileptic disorders. J Korean Neurosurg Soc. 2019;62:272–287.
   PubMed Web of Science ®Google Scholar
• Romaniello R, Arrigoni F, Cavallini A, et al. Brain malformations and mutations in α- and β-tubulin genes: a review of the literature and description of two new cases. Dev Med Child Neurol. 2014;56:354–360.
   PubMed Web of Science ®Google Scholar
• Parrini E, Ramazzotti A, Dobyns WB, et al. Periventricular heterotopia: phenotypic heterogeneity and correlation with filamin A mutations. Brain. 2006;129:1892–1906.
   PubMed Web of Science ®Google Scholar
• Kielar M, Phan Dinh Tuy F, Bizzotto S, et al. Mutations in Eml1/EML1 lead to ectopic progenitors and neuronal heterotopia in mouse and human. Med Sci. 2014;30:1087–1090.
   Google Scholar
• Shahwan A, Farrell M, Delanty N, et al. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 2005;4:239–248.
   PubMed Web of Science ®Google Scholar
• Kälviäinen R. Progressive myoclonus epilepsies. Semin Neurol. 2015;35:293–299.
   PubMed Web of Science ®Google Scholar
• Muona M, Berkovic SF, Dibbens LM, et al. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. Nat Genet. 2015;47:39–46.
   PubMed Web of Science ®Google Scholar
• Vanni N, Fruscione F, Ferlazzo E, et al. Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy. Ann Neurol. 2014;76:206–212.
   PubMed Web of Science ®Google Scholar
• Opri R, Fabrizi GM, Cantalupo G, et al. Progressive myoclonus epilepsy in congenital generalized lipodystrophy type 2: report of 3 cases and literature review. Seizure. 2016;42:1–6.
   PubMed Web of Science ®Google Scholar
• Franceschetti S, Gambardella A, Canafoglia L, et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia. 2006;47:640–643.
   PubMed Web of Science ®Google Scholar
• Canafoglia L, Gennaro E, Capovilla G, et al. Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations. Epilepsia. 2012;53:2120–2127.
   PubMed Web of Science ®Google Scholar
• Ferlazzo E, Canafoglia L, Michelucci R, et al. Mild Lafora disease: clinical, neurophysiologic, and genetic findings. Epilepsia. 2014;55:e129–33.
   PubMed Web of Science ®Google Scholar
• Casciato S, Gambardella S, Mascia A, et al. Severe and rapidly-progressive Lafora disease associated with NHLRC1 mutation: a case report. Int J Neurosci. 2017;127:1150–1153.
   PubMed Web of Science ®Google Scholar
• Striano P, Vari MS, Mazzocchetti C, et al. Management of genetic epilepsies: from empirical treatment to precision medicine. Pharmacol Res. 2016;107:426–429.
   PubMed Web of Science ®Google Scholar
• Klepper J. GLUT1 deficiency syndrome in clinical practice. Epilepsy Res. 2012;100:272–277.
   PubMed Web of Science ®Google Scholar
• Pearson TS, Akman C, Hinton VJ, et al. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep. 2013;13:342.
   PubMed Web of Science ®Google Scholar
• Mercimek-Mahmutoglu S, Cordeiro D, Cruz V, et al. Novel therapy for pyridoxine dependent epilepsy due to ALDH7A1 genetic defect: L-arginine supplementation alternative to lysine-restricted diet. Eur J Paediatr Neurol. 2014;18:741–746.
   PubMed Web of Science ®Google Scholar
• Platzer K, Yuan H, Schutz H, et al. GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J Med Genet. 2017;54:460–470.
   PubMed Web of Science ®Google Scholar
• Ramaswami M, Gautam M, Kamb A, et al. Human potassium channel genes: molecular cloning and functional expression. Mol Cell Neurosci. 1990;1:214–223.
   PubMedGoogle Scholar
• Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia. 2016;57:2019–2030.
   PubMed Web of Science ®Google Scholar
• Millichap JJ, Park KL, Tsuchida T, et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016;2:e96.
   PubMed Web of Science ®Google Scholar
• Ihara Y, Tomonoh Y, Deshimaru M, et al. Retigabine, a Kv7.2/Kv7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 mutations. PLoS One. 2016;11:e0150095.
   PubMed Web of Science ®Google Scholar
• Bearden D, Strong A, Ehnot J, et al. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol. 2014;76:457–461.
   PubMed Web of Science ®Google Scholar
• Yang YR, Kang DS, Lee C, et al. Primary phospholipase C and brain disorders. Adv Biol Regul. 2016;61:80–85.
   PubMedGoogle Scholar
• Campistol J, Plecko B. Treatable newborn and infant seizures due to inborn errors of metabolism. Epileptic Disord. 2015;17:229–242.
   PubMed Web of Science ®Google Scholar
• Tanabe Y, Taira T, Shimotake A, et al. An adult female with proline-rich transmembrane protein 2 related paroxysmal disorders manifesting paroxysmal kinesigenic choreoathetosis and epileptic seizures. Rinsho Shinkeigaku. 2019;59:144–148.
   PubMedGoogle Scholar
• Chou IC, Lin SS, Lin WD, et al. Successful control with carbamazepine of family with paroxysmal kinesigenic dyskinesia of PRRT2 mutation. Biomedicine (Taipei). 2014;4:15.
   PubMedGoogle Scholar
• Howell KB, McMahon JM, Carvill GL, et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology. 2015;85:958–966.
   PubMed Web of Science ®Google Scholar
• Sanders SJ, Campbell AJ, Cottrell JR, et al. Progress in understanding and treating SCN2A-mediated disorders. Trends Neurosci. 2018;41:442–456.
   PubMed Web of Science ®Google Scholar
• Dilena R, Striano P, Gennaro E, et al. Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy. Brain Dev. 2017;39:345–348.
   PubMed Web of Science ®Google Scholar
• Flor-Hirsch H, Heyman E, Livneh A, et al. Lacosamide for SCN2Arelated intractable neonatal and infantile seizures. Epileptic Disord. 2018;20:440–446.
   PubMed Web of Science ®Google Scholar
• Johannesen KM, Gardella E, Encinas AC, et al. The spectrum of intermediate scn8a-related epilepsy. Epilepsia. 2019;60(5):830-844.
   PubMed Web of Science ®Google Scholar
• Liu Y, Schubert J, Sonnenberg L, et al. Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability. Brain. 2019;142:376–390.
   PubMed Web of Science ®Google Scholar
• Schwantje M, Verhagen LM, van Hasselt PM, et al. Glucose transporter type 1 deficiency syndrome and the ketogenic diet. J Inherit Metab Dis. 2019Oct 12. doi: 10.1002/jimd.12175. [Epub ahead of print]
   PubMedGoogle Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153–2163.
   PubMed Web of Science ®Google Scholar
• Okanishi T, Fujimoto A, Nishimura M, et al. The efficacy of everolimus for refractory seizures in childhood onset epilepsy with tuberous sclerosis complex. Brain Nerve. 2019;71:611–616.
   PubMedGoogle Scholar
• Canpolat M, Gumus H, Kumandas S, et al. The use of rapamycin in patients with tuberous sclerosis complex: long-term results. Epilepsy Behav. 2018;88:357–364.
   PubMed Web of Science ®Google Scholar
• Schubert-Bast S, Rosenow F, Klein KM, et al. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives. Epilepsy Behav. 2019;91:94–98.
   PubMed Web of Science ®Google Scholar
• Baumgart A, Spiczak S, Verhoeven-Duif NM, et al. Atypical vitamin B6 deficiency: a rare cause of unexplained neonatal and infantile epilepsies. J Child Neurol. 2014;29:704–707.
   PubMed Web of Science ®Google Scholar
• Dibbens LM, de Vries B, Donatello S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet. 2013;45:546–551.
   PubMed Web of Science ®Google Scholar
• Sadowski K, Kotulska-Jóźwiak K, Jóźwiak S, et al. Role of mTOR inhibitors in epilepsy treatment. Pharmacol Rep. 2015;67:636–646.
   PubMed Web of Science ®Google Scholar
• Griffith JL, Wong M. The mTOR pathway in treatment of epilepsy: a clinical update. Future Neurol. 2018;13:49–58.
   PubMed Web of Science ®Google Scholar
• Catterall WA. Dravet syndrome: a sodium channel interneuronopathy. Curr Opin Physiol. 2018;2:42–50.
   PubMed Web of Science ®Google Scholar
• Sun Y, Paşca SP, Portmann T, et al. A deleterious Nav1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet syndrome patients. Elife. 2016;5:e13073.
   PubMed Web of Science ®Google Scholar
• Perucca P. Genetics of focal epilepsies: what do we know and where are we heading? Epilepsy Curr. 2018;18:356–362.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68:18–34 e3.
   PubMed Web of Science ®Google Scholar
• Richards KL, Milligan CJ, Richardson RJ, et al. Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death. Proc Natl Acad Sci USA. 2018;115:E8077–85.
   PubMed Web of Science ®Google Scholar
• Therapeutics S. Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy. 2018. cited 2018 Dec 26. https://www.stoketherapeutics.com/wpcontent/uploads/Stoke-PR-Dec-1-1.pdf
   Google Scholar
• Perucca P, Perucca E. Identifying mutations in epilepsy genes: impact on treatment selection. Epilepsy Res. 2019;152:18–30.
   PubMed Web of Science ®Google Scholar
• Pierson TM, Yuan H, Marsh ED, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol. 2014;1:190–198.
   PubMed Web of Science ®Google Scholar
• De Sarro G, Ongini E, Bertorelli R, et al. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol. 1994;262:11–19.
   PubMed Web of Science ®Google Scholar
• Reif PS, Tsai MH, Helbig I, et al. Precision medicine in genetic epilepsies: break of dawn? Expert Rev Neurother. 2017;17:381–392.
   PubMed Web of Science ®Google Scholar
• Volkmann RA, Fanger CM, Anderson DR, et al. MPX-004 and MPX-007: new pharmacological tools to study the physiology of NMDA receptors containing the GluN2A subunit. PLoS One. 2016;11:e0148129.
   PubMed Web of Science ®Google Scholar
• Zhu S, Paoletti P. Allosteric modulators of NMDA receptors: multiple sites and mechanisms. Curr Opin Pharmacol. 2015;20:14–23.
   PubMed Web of Science ®Google Scholar
• Addis L, Virdee JK, Vidler LR, et al. Epilepsy associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency-molecular profiling and functional rescue. Sci Rep. 2017;7:66.
   PubMed Web of Science ®Google Scholar
• Strehlow V, Heyne HO, Vlaskamp DRM, et al. GRIN2A-related disorders: genotype and functional consequence predict phenotype. Brain. 2019;142:80–92.
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
   PubMed Web of Science ®Google Scholar
• McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134–1143.
   PubMed Web of Science ®Google Scholar
• Baulac S, Ishida S, Marsan E, et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol. 2015;77:675–683.
   PubMed Web of Science ®Google Scholar
• Mikati MA, Jiang YH, Carboni M, et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol. 2015;78:995–999.
   PubMed Web of Science ®Google Scholar
• Billakota S, Andresen JM, Gay BC, et al. Personalized medicine: vinpocetine to reverse effects of GABRB3 mutation. Epilepsia. 2019;60:2459–2465.
   PubMedGoogle Scholar